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Abstract
Bacground/Aim. Sjögren’s syndrome is a chronic autoimmune
systemic disease characterized by polyglandular tissue destruction,
leading to keratoconjunctivitis sicca and xerostomia. These patients
have 44-fold increased risk of developing salivary gland lymphoma,
of which 80% are marginal zone (MALT) type. Having in mind
that criteria for distinguishing benign lymphoepithelial lesions from
MALT lymphoma are obscure, the aim of this study was to pro-
vide practical information that could be integrated into diagnostic
practice.  Methods. Among 32 parotidectomies, 27 cases were
identified as having benign lymphoepithelial disorders and 5 cases
low grade MALT lymphoma. Histological sections were stained
routinely with hematoxylin and eosin (H&E and special stains.
Immunohistochemical study was performed by LSAB2 method,
by using primary antibodies for CD20, CD3, Kappa and Lambda
light chains and Cytokeratin (Dako Denmark). Results. The 27
patients with Sjögren’s sialoadenitis (22 women and 5 men), and 5
patients with MALT lymphoma (only women) were included in
this analysis. According to the Ann Harbor Classification, all pa-
tients with MALT lymphoma had stage IE. Both groups of pa-
tients had an indolent clinical course, except permanent, rapid pa-
rotid enlargement in the patients with MALT lymphoma. His-
tologically, the periductal lymphoid infiltrate, gradually extended to
the acini, completely replacing them by a sea of polyclonal lym-
phocytes, immunoblasts, germinal centers and plasma cells (con-
firmed immunohistochemically), but sparing the ducts and pre-
serving lobular appearance. The histological feature of salivary
gland MALT lymphoma included heterogeneous B-cell infiltrate
that totally or subtotally had effaced the normal glandular struc-
ture. Malign lymphoepithelial lesions, representing infiltration of
the ductal and epithelial structures by monoclonal neoplastic B-
cells, positive for CD20, were highlighted by antibody to cyto-
keratin.  Conclusion. The optimal diagnosis of salivary gland
MALT lymphoma requires careful integration of clinical, mor-
phological and immunohistochemical results.
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Apstrakt
Uvod/Cilj. Sjegrenov sindrom je hronična autoimuna si-
stemska bolest okarakterisana poliglandularnom tkivnom
destrukcijom, suvim keratitisom i suvim ustima. Ovi bo-
lesnici imaju 44 puta veći rizik od razvoja limfoma, pri
čemu je kod 80% njih prisutan MALT tip. Zbog nejasnih
kriterijuma za razlikovanje benignih limfoepitelnih lezija
pljuvačnih žlezda od MALT limfoma, cilj ove analize bio
je obezbeđivanje praktičnih, kliničkih, histopatoloških i
imunohistohemijskih informacija o njima. Metode. Od
32 parotidektomije, kod 27 nađen je Sjegrenov sijaloade-
nitis, a kod 5 MALT limfom. Laboratorijski preseci deb-
ljine 4 µm bojeni su hematoksilin/eozin (HE), Van Gie-
son, AB-PAS i LSAB2 metodama, uz korišćenje antitela
na: CD3, CD20, kappa i lambda lake lance i
panCytokeratin antigene.  Rezultati. Analizom je bilo
obuhvaćeno 27 bolesnika (22 žene i 5 muškaraca) sa Sje-
grenovim sijalodenitisom i pet bolesnika (samo žene) sa
MALT limfomom. U skladu sa Ann Harbor klasifikacijom
svi bolesnici sa MALT limfomom bili su u stadijumu IE.
Obe grupe bolesnika imale su blagi klinički tok, sem br-
žeg povećanja jedne parotidne žlezde kod onih sa limfo-
mom. Za razliku od benignih limfoepitelnih lezija,
MALT limfom odlikovao se difuznim i gustim mono-
klonskim B-ćelijskim infiltratom, uz brisanje normalne
građe pljuvačne žlezde i malignim limfoepitelnim lezija-
ma infiltrovanim monoklonskim tipom B limfocita pot-
puno ili delimično. Maligne limfoepitelne lezije, prikaza-
ne kao infiltracije duktusnih i epitelnih struktura mono-
klonskim neoplastičnim B-ćelijama pozitivnim na CD 20,
prikazale su se pomoću antitela na citokeratin. Zaklju-
čak. Za optimalnu dijagnozu MALT limfoma pljuvačne
žlezde neophodni su klinički, morfološki i imunohisto-
hemijski nalazi.
Ključne reči:
sjegrenov sindrom; limfom, malt; dijagnoza,
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Introduction
Sjögren’s syndrome (SS) was named after the Swedish
ophthalmologist Henrik Sjögren who presented his doctoral
thesis in 1933 
1. More recently, a number of studies have
presented ground-breaking reports on SS, which now can be
considered as a classical finding 
2. Sjögren’s syndrome is a
chronic autoimmune systemic disease characterized by poly-
glandular tissue destruction leading to keratoconjunctivitis
sicca (KCS) and xerostomia
 3–10. Sjögren’s syndrome is a
worldwide disease and may occur in all ages. However, the
peak incidence is in the fourth and fifth decades of life with a
female/male ratio 9:1. It may develop alone (primary), or in
association with an autoimmune diseases (secondary), the
most frequent being rheumatoid arthritis and systemic lupus
erythematosus
 3, 8, 10. Clinical course of SS is a slowly pro-
gressing disease, without rapid deterioration in salivary
function, with systemic markers of disease activity, or dra-
matic changes in symptoms 
3, 7, 8. These patients have a 44-
fold increased risk of developing salivary gland lymphoma,
of which 80% are low-grade B cell lymphomas of mucosa-
associated lymphoid tissue (MALT)
 6. The criteria for distin-
guishing benign lymphoepithelial lesions from MALT lym-
phoma in salivary glands are obscure and controversial
 5, 11–
18. There are few studies on the natural course of primary SS,
but it has been described as a stepwise, gradual progression
from a disorder mainly in exocrine glands, to systemic ex-
traglandular features and finally to lymphoid neoplasia de-
velopment
 2. In general, primary SS is characterized by a sta-
ble and rather mild course of glandular or extraglandular
manifestations, in contrast to the increased risk for develop-
ment of malignant lymphoma
 2. But, in the study on survi-
vorship in a population-based cohort followed from l976 to
l992, the authors did not demonstrate an increased mortality
of patients with primary SS 
16. Having in mind that the dis-
tinction between sialoadenitis usually in association with SS
and early MALT lymphoma has difficulty proved using
clinical criteria alone, we have decided to study the clinical,
histopathological and immunohistochemical features of these
diseases of the parotid gland.
Methods
Among 32 patients with parotidectomies, induced by
Sjögren’s sialoadenitis, sialoadenitis calculosis chronica or
parotid gland tumors, 27 cases were identified as primary SS
with benign lymphoepithelial disorder and 5 cases with
MALT lymphoma. These cases spanned the period 2003
through 2007 years. The resected tissue specimens were
fixed in 10% buffered formalin and embedded in paraffin.
Paraffin tissue sections were cut at 5 µm and stained rou-
tinely with hematoxylin and eosine (H&E). The special
stains used included periodic acid-Schiff (PAS), Giemsa and
silver impregnation for reticulin. Immunohistochemical
study was performed by using labeled streptavidin-biotin
(LSAB) Kit (DAKO Denmark). Hematoxylin was used for
counterstaining. The sites of peroxidase were visualized with
diaminobensidine tetrachloride. Pretreatment (antigen re-
trieval) was performed by heating tissue sections in 800W
microwave oven for 15 minutes with 0.1 mol/L citrate pH=6.
Following primary monoclonal antibodies were used: pan-
Cytokeratin (epithelial marker), CD20 (B-lymphocyte
marker), CD3 (T-lymphocyte marker) and light chains of
kappa and lambda (marker for polyclonal lymphocytes). En-
dogenous peroxidase activity was blocked with 3% hydrogen
peroxide solution. Nonspecific binding was reduced with
10% normal goat serum block before incubation. Appropri-
ate positive and negative controls were included.
Results
Of 32 patients with parotidectomies, Sjögren’s sialo-
adenitis was discovered in 27 patients (22 women and 5
men) and MALT lymphoma in 5 women. The median age at
the time of parotidectomy was 52 years for patients with
Sjögren’s sialoadenitis and 59 years for patients with MALT
lymphoma. The duration of sicca symptoms (keratokonjunc-
tivitis sicca and xerostomia) was from 4.7 to 9.5 years for
Sjögren’s sialoadenitis and, about six years before the diag-
nosis for MALT lymphoma. The patients were typically pre-
sented with a painless mass that showed episodic enlarge-
ment. Two of the patients had a facial nerve paresis and pain.
The important clinical sign of MALT lymphoma was perma-
nent, rapid enlarged of parotid gland.
Histologically, periductal and perivascular dense round
cell infiltrate extended to the acini and formed lymphoid fol-
licles, often with germinal centers (Figure 1). Somewhere,
the parotid glands were completely replaced by a sea of
polyclonal lymphocytes, plasma cells and macrophages. The
stroma of the gland was preserved, an appearance that helps
to differentiate this disorder from a lymphoma. Slightly di-
lated ducts without acini, the important characteristic of
glandular atrophy, were seen everywhere (Figure 2). The
characteristics of the late stage in the course of Sjögren’s’
sialoadenitis were also seen, predominantly atrophy of the
acini, fibrosis (Figure 3), hyalinization, fatty infiltration and
nests of oncocytic cell degeneration (Figure 4). Proliferating
lymphoepithelial cells surrounded remnants of the damaged
ducts, forming so-called benign lymphoepithelial islands.
Fig. 1 – Marked acinar atrophy, mononuclear infiltrate and
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Fig. 2 – Periductal lymphocytic infiltrate with sialoduct
ectasia (HE ×200)
Fig. 3 – Atrophic glands replaced by lymphoid infiltrate,
lymphatic follicles and wide stromal fibrosis  (HE ×200)
Fig. 4 – Oncocytic adenomatoid metaplasia in the atrophic
parotid gland tissue (HE ×400)
Immunophenotypic analysis, performed on paraffin
sections, demonstrated that the majority of inflammatory
cells were of polyclonal type.
The parotid gland was diffusely and extensively infil-
trated by neoplastic lymphoid cells that disintegrated it,
leaving only the clusters of degenerative cells and residual
ducts among the lymphoid infiltrate (Figure 5). The lym-
phoma cells showed varied cytological appearances, often
with individual specimens. The most numerous cells of sali-
vary MALT lymphoma had small to medium-sized, slightly
irregular nuclei with moderately dispersed chromatin and in-
conspicuous nucleoli, resembling those of centrocytes; they
had relatively abundant, pale cytoplasm. With the accumula-
tion of more palecytoplasm, and distinct cell borders, neo-
plastic cells had the monocytoid appearance (Figure 6), or
resembled small mature lymphocytes. Somewhere, variable
numbers of plasma cells were frequently present, often adja-
cent to the epithelium. Scattered large transformed centro-
blast- or immunoblast-like cells were usually dispersed
throughout the lymphoma. The immunophenotype of the
neoplastic cells of MALT lymphoma was CD20 +, high-
lighting the extensive B-cell infiltrate, particularly around
ducts (Figure 7). An important diagnostic feature of MALT
lymphoma at many sites was the presence of malign (lym-
phoepithelial lesion (LEL) defined by the infiltration and de-
struction of the epithelial structures, often together with eo-
sinophilic degeneration, by aggregates of neoplastic lym-
phoid cells and lymphoid follicles, highlighted by panCyto-
keratin and by CD20 (Figures 8 and 9).
Fig. 5 – Salivary gland is replaced by a dense and extensive
lymphocytic infiltrate with residual two ducts (HE ×400)
Fig. 6 – Lymphoepithelial lesion with numerous pale lym-
phoid cells. These centrocyte-like/monocytoid appearing
cells extended beyond them, forming the confluent sheets
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Fig. 7 – Immunophenotypic staining demonstrated that the
majority of cells are CD20+ (LSAB ×400)
Fig. 8 – Lymphoepithelial lesions – positive expression of
panCytoceratin inside ductal epithelium and negative inside
infiltrative lymphocyte cell field (LSAB ×400)
Fig. 9 – Lymphoepithelial lesions – positive expression of
CD20 inside ductal epithelium, infiltrated by lymphocytes
(LSAB ×400)
The tumor cells of MALT lymphoma expressed the
marginal zone cell-associated antigens (CD20), immuno-
globulin light chain restriction and the lack of CD3 antigen,
not only in lymphocytes adjacent to the lymphoepithelial le-
sions, but also within the lymphoepithelial lesions (Figures 9).
Discussion
There are clinical evidences that SS and lymphoma are
linked. The risk of B cell non-Hodgkin lymphoma (NHL) is
by 44 times greater in patients with SS than in healthy
population affecting about 5 percent of patients with
SS
 2, 6, 13–16, 19–25. There are few studies on the natural course
of primary SS, but it has been described as a stepwise, grad-
ual progression of lymphoid disorder mainly in exocrine
glands, to systemic extraglandular features and finally to
lymphoid neoplasia development
 2, 26. However, in general
primary SS is characterized by a stable and rather mild
course of glandular or extraglandular manifestations, in con-
trast to the increased risk for development of malignant lym-
phoma
 2, 25–30. In a study on survivorship, in a population-
based cohort followed from 1976 to 1992, the authors did not
demonstrate increased mortality of patients with primary
SS 
18. The salivary gland lymphoid infiltrates, associated
with LEL, include broad spectrum of lympho (plasmocytic)
proliferations that range from benign to small B cell lym-
phomas to large B- ell lymphomas
 12, 28–33. Depending on the
precise type of proliferation, they go by a variety of different
terms: benign lymphoepithelial (myoepithelial), sialoadeni-
tis/extranodal marginal zone B cell lymphomas (MZL) or
MALT type / high grade MALT lymphoma (diffuse large B
cell lymphoma)
 26–30. About half of the cases are associated
with SS or another autoimmune disorder such as rheumatoid
arthritis, that was also confirmed by us in one case
 25, 30.
Whereas most lesions with LEL in the past were considered
benign but the categorization of these lesions now has be-
come confusing due to varying criteria for lymphoma and
recognition by some of borderline lesions or a “clonal disor-
der of uncertain malignant potential”
 25–28.
SS presents with a wide variety of clinical features. On-
set of the disease is insidious and patients have difficulty in
determing when the disease actually started. Keratoconjunc-
tivitis sicca and xerostomia (so-called sicca complex) are the
main clinical presentations in adults, whereas bilateral pa-
rotid swelling can be an obvious sign at juvenile disease on-
set 
2. More than half of the patients may develop the ex-
traglandular manifestations during the evolution of the dis-
ease. Occasionally, systemic features may lead to the diagno-
sis
 2, 25, 30.
Anti-inflammatory therapy in primary SS significantly
improved subjective symptoms and objective ocular
signs 
2, 8, 22, 33–37. Artificial tears and soft contact lenses of-
ten alleviate the patient’s ocular complains, and are of im-
portance in preventing corneal damage and conjunctivi-
tis 
2, 37. However, we did not find evidence that anti-
inflammatory treatment increases tear production in these
patients.
The management of dry mouth aims to prevent and treat
infections, periodontal disease and dental caries. To reduce
the risk of caries, it is necessary to maintain a good oral hy-Volumen 66, Broj 12 VOJNOSANITETSKI PREGLED Strana 959
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giene. Artificial saliva products and special toothpaste may
also be benefit for certain patients, and fluoride supplemen-
tation is advocated. Eradication of oral candidiasis usually
provides significant improvement of oral symptoms
 2, 26. Oral
pilocarpine has been shown to be a safe treatment and pro-
vide significant subjective and objective benefits for patients
suffering from symptoms associated with xerostomia. An-
other therapy includes systemic use of interferon-alpha,
which may be of benefit for the symptoms associated with
xerostomia.
The optimal therapeutic strategy for salivary MALT
lymphoma is not yet defined and depends on the clinical
stage of removed MALT lymphoma
 2, 12, 15, 33. On the basis of
some retrospective analysis, the authors have concluded that
there is no significant difference in outcomes among patients
undergoing a variety of treatment modalities (surgery, ra-
diotherapy, chemotherapy) and those undergoing to long-
term follow-up
 2, 12, 15, 26, 28, 33–37.
Among the possible etiologic and triggering factors in-
volved in Sjögren’s  syndrome, the discussion on relation-
ship between viral infections causing the development of
autoimmune reactions, began some decades ago
 3, 12, 23, 24. The
putative role of different viruses can be viewed in the light
that salivary glands are a site of latent viral infections and
that lymphotropic viruses have the potential to trigger the
autoimmune process. Some of the immunoreactive regions
within the La/SS–B protein have been found to have se-
quence similarities with proteins of Epstein-Barr virus
(EBV) and HIV-1. It seems reasonable that these viruses can
promote autoantibody production
 3, 24, 26, 30.
Immunohistological analysis of lymphoid cell infiltra-
tion in the exocrine glands in SS shows a predominance of
T-cells with fewer B-cells and macrophages
 3, 23, 24.  The ma-
jority of T-cells in the lymphocytic infiltrates are CD4+ T-
helper cells with CD4/CD8 ratio well over two. Most of
these T-cells bear the memory phenotype and may contribute
significantly to B cell hyperactivity. The B-cells make up
roughly 20% of the infiltrating cell population in the affected
glands, producing immunoglobulins with autoantibody ac-
tivity. About 75% of patients have rheumatoid factor re-
gardless of whether coexisting rheumatoid arthritis is present
or not
 26, 30–36. Rheumatoid factor is also commonly found in
saliva, tears and the circulation. Antinuclear antibodies
(ANAs) are detected in 50–80% of patients and a positive LE
test result is present in 25%
 35. Most important, however, are
antibodies directed against two RNP antigens, SSA (Ro) and
SSB(La) which can be detected in up to 90% of patients 
2, 35.
Those with high titers of antibodies to SSA are more likely
to have extraglandular manifestations, such as cutaneous
vasculitis and CNS disease 
35. The finding of serum autoan-
tibodies directed against the muscarinic M3 receptor (ex-
pressed in salivary and lacrimal glands) in the majority of
patients is an important advance in understanding the patho-
genesis of impaired glandular function in SS
 2. Oligoclonal or
monoclonal B cell expansion, arising mainly from salivary
glands but also from visceral organs and lymph nodes, has
been reported to occur in 14–100% of SS patients 
18–23. In
this respect, SS appears to be a crossroad between autoim-
munity and malignancy and it is suggested that patients with
evidence of clonal expansions of B-cells in their salivary
glands are at high risk of developing malignant lym-
phoma
 2, 26, 30–36. Sjögren’s syndrome represents a pathologi-
cal model of the evolution from polyclonal B lymphocyte
activation to oligoclonal/monoclonal B-cell expansion,
which may culminate in the development of a malignant
lymphoproliferative disease 
33–35. Different phases of this
process are usually marked by the appearance of antigen-
driven activated B-cell clones, which are commonly IgM-
positive and with rheumatoid factor (RF) activity. However,
the antigen able to trigger B-cell proliferation is still un-
known. Immunoglobuline products of the neoplastic B cells
were RF. Contrary to the expectations, they did not react
with nuclear or cytoplasmic antigens, double-stranded DNA,
self antigens commonly bound by natural autoantibodies, or
SG tissue
 33–36.
The reported data on genetic abnormalities such as nu-
merical chromosomal aberrations, translocations, mutations
and inactivation of the tumor suppressor genes, p53 and p16
in salivary MALT lymphoma are contradictory 
2, 21, 33–35.
An optimal therapeutic strategy for salivary MALT
lymphoma has not yet been defined and depends on the
clinical stage of a removed MALT lymphoma
 2, 12, 15, 33. On
the basis of some retrospective analysis, the authors have
concluded that there is no a significant difference in out-
comes among patients undergoing a variety of treatment mo-
dalities (surgery, radiotherapy, chemotherapy) and those un-
dergoing a long-term follow-up 
2, 12, 15, 26, 28, 33–37.
Conclusion
Based on the results of this study we consider that an
optimal diagnosis of MALT lymphoma requires a careful
integration of the following clinical, histopathological and
immunohistochemical findings: rapid and persistent en-
largement of the parotid gland, destruction of lobular parotid
gland structure by extensive and dense lymphoid infiltrate,
presence of monoclonal B-cell infiltrate and presence of ma-
lign lymphoepithelial lesions.
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